
-
Terns Pharmaceuticals NASDAQ:TERN Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns’ programs are based on clinically validated and complementary mechanisms of action to address the multiple hepatic disease processes of NASH in order to drive meaningful clinical benefits for patients.
Location: | Website: ternspharma.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-101.4M
Cash
372.8M
Avg Qtr Burn
-18.69M
Short % of Float
12.06%
Insider Ownership
0.26%
Institutional Own.
-
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Phase 2 Initiation | ||
TERN-501 (THR-B Agonist) +/- TERN-101 (FXR agonist) Details Non-alcoholic steatohepatitis | Phase 2a Update | |
TERN-701 (Allosteric BCR-ABL inhib) Details Chronic myelomonocytic leukemia | Phase 1 Data readout | |
TERN-201 (VAP-1 inhibitor) Details Non-alcoholic steatohepatitis | Failed Discontinued | |
TERN-101 (FXR agonist) Details Non-alcoholic steatohepatitis | Failed Discontinued |